HA
PTLA

Harbor Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Harbor Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,379
Closed -$436K – 179
2018
Q3 		$436K Hold
16,379
– – 0.14% 102
2018
Q2 		$619K Hold
16,379
– – 0.2% 78
2018
Q1 		$535K Buy
16,379
+9,229
+129% +$405K 0.18% 81
2017
Q4 		$348K Buy
+7,150
New +$362K 0.12% 115

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Harbor Advisors's PTLA Position: Q4 2018 in Review

Harbor Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 16,379 shares — an estimated $436K sold.

Harbor Advisors first reported a position in PTLA in Q4 2017 and held it in 4 quarters. The position peaked at $619K in Q2 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Harbor Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Harbor Advisors sold 16,379 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $436K.
  • Harbor Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
  • Harbor Advisors's Portola Pharmaceuticals, Inc. position peaked at $619K in Q2 2018.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Harbor Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.